The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

Yael Eshet; Noam Tau; Sara Apter; Noam Nissan; Keren Levanon; Rinat Bernstein-Molho; Ofer Globus; Amit Itay; Tal Shapira; Cecilie Oedegaard; Malka Gorfine; Michal Eifer; Tima Davidson; Einav Gal-Yam; Liran Domachevsky

doi:10.1097/rlu.0000000000004540

The Role of ⁶⁸Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

Yael Eshet, Noam Tau, Sara Apter, Noam Nissan, Keren Levanon, Rinat Bernstein-Molho, Ofer Globus, Amit Itay, Tal Shapira, Cecilie Oedegaard, Malka Gorfine, Michal Eifer, Tima Davidson, Einav Gal-Yam, Liran Domachevsky

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

Original language	English
Pages (from-to)	228-232
Number of pages	5
Journal	Clinical Nuclear Medicine
Volume	48
Issue number	3
DOIs	https://doi.org/10.1097/rlu.0000000000004540
State	Published - 1 Mar 2023

Keywords

FAPI-04
PET/CT
breast neoplasms
carcinoma
lobular

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/rlu.0000000000004540

Cite this

Eshet, Y., Tau, N., Apter, S., Nissan, N., Levanon, K., Bernstein-Molho, R., Globus, O., Itay, A., Shapira, T., Oedegaard, C., Gorfine, M., Eifer, M., Davidson, T., Gal-Yam, E., & Domachevsky, L. (2023). The Role of ⁶⁸Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer. Clinical Nuclear Medicine, 48(3), 228-232. https://doi.org/10.1097/rlu.0000000000004540

@article{54ef5c0d9cae4a06af96cd0c83041cb6,

title = "The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer",

abstract = "Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.",

keywords = "FAPI-04, PET/CT, breast neoplasms, carcinoma, lobular",

author = "Yael Eshet and Noam Tau and Sara Apter and Noam Nissan and Keren Levanon and Rinat Bernstein-Molho and Ofer Globus and Amit Itay and Tal Shapira and Cecilie Oedegaard and Malka Gorfine and Michal Eifer and Tima Davidson and Einav Gal-Yam and Liran Domachevsky",

year = "2023",

month = mar,

day = "1",

doi = "10.1097/rlu.0000000000004540",

language = "الإنجليزيّة",

volume = "48",

pages = "228--232",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

AU - Eshet, Yael

AU - Tau, Noam

AU - Apter, Sara

AU - Nissan, Noam

AU - Levanon, Keren

AU - Bernstein-Molho, Rinat

AU - Globus, Ofer

AU - Itay, Amit

AU - Shapira, Tal

AU - Oedegaard, Cecilie

AU - Gorfine, Malka

AU - Eifer, Michal

AU - Davidson, Tima

AU - Gal-Yam, Einav

AU - Domachevsky, Liran

PY - 2023/3/1

Y1 - 2023/3/1

N2 - Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

AB - Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

KW - FAPI-04

KW - PET/CT

KW - breast neoplasms

KW - carcinoma

KW - lobular

UR - http://www.scopus.com/inward/record.url?scp=85147318173&partnerID=8YFLogxK

U2 - 10.1097/rlu.0000000000004540

DO - 10.1097/rlu.0000000000004540

M3 - مقالة

C2 - 36638243

SN - 0363-9762

VL - 48

SP - 228

EP - 232

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 3

ER -